Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.80 |
| ▸ | PPARA | Q07869 | 15/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486494 | 0.93 | PPARG (0.69) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6476928 | 0.92 | PPARG (0.77) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5913603 | 0.89 | PPARG (1.00) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29496192 | 0.89 | PPARG (1.00) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6476910 | 0.87 | PPARG (0.92) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5913369 | 0.86 | PPARG (0.95) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5913647 | 0.86 | PPARG (0.81) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5913642 | 0.86 | PPARG (0.81) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6477570 | 0.86 | PPARG (0.87) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6477333 | 0.85 | PPARG (0.78) | PPARGPPARANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919362-B2 | Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2005-07-19 | — | — | US | disclosed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | PPARG 414/4885PPARA 845/4885NPC1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.